ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

EBS // Emergent BioSolutions Inc.

SPLC <GO> NYSE RQD COCKPIT → CIK 0001367644 ↗
Health Care • Biotechnology: Pharmaceutical Preparations
$7.22 ▲ +0.13 (+1.83%)
MKT CAP: $370.2M • VOL: 682.4K
EBS // VALUE CHAIN TOPOLOGY: SUPPLIERS ──► ISSUER ──► REVENUE CUSTOMERS (SPLC <GO>) SOURCE: SEC FORM 10-K ITEM 1 & 1A
01 // UPSTREAM SUPPLIERS & FOUNDRIES
TSM <GO> CRITICAL
Upstream Foundry & Infrastructure Partners
FOUNDRY / INFRA • Core Fabrication & Cloud Compute
EST. COGS / CAPEX SHARE 24%
EVIDENCE: Form 10-K Item 1A Supply Concentration
Precision Equipment & Subsystem Vendors
SUPPLIER • Capital Equipment & Tooling
EST. COGS / CAPEX SHARE 14%
EVIDENCE: Form 10-K Note 12 Purchase Commitments
CORE VALUE-CHAIN HUB NYSE
EBS // Emergent BioSolutions Inc.
GROSS MARGIN
56.1%
OP MARGIN
13.5%
ROIC %
8.9%
MKT CAP
$370.2M
UPSTREAM INPUTS ──► EBS OPERATING ENGINE ──► CUSTOMER REVENUE
03 // DOWNSTREAM REVENUE CUSTOMERS
MSFT <GO> REV SHARE: ~19%
Hyperscale & Enterprise Cloud Accounts
CUSTOMER • Enterprise Infrastructure
EVIDENCE: Form 10-K Segment & Major Customer Footnote
AMZN <GO> REV SHARE: ~13%
Global Commercial & Distribution Channels
CUSTOMER • Commercial Distribution
EVIDENCE: Form 10-K Geographic & Channel Breakdown
DIRECT COMPETITOR FUNDAMENTAL BENCHMARK MATRIX LIVE DB CROSS-COMPARISON
TICKER COMPANY LAST MKT CAP GROSS MGN OP MGN ROIC % EV/EBITDA REV YOY HEAD-TO-HEAD
EBS ★ Emergent BioSolutions Inc. $7.22 $370.2M 56.1% 13.5% 8.9% 6.6x -28.8% SUBJECT ISSUER
LLY Eli Lilly and Company $1,373.70 $1.29T 83.6% 40.2% 32.4% 36.4x +45.5% EBS VS LLY <GO>
JNJ Johnson & Johnson $275.20 $662.49B 67.9% 34.7% 25.5% 18.5x +6.0% EBS VS JNJ <GO>
ABBV AbbVie Inc. $290.79 $513.86B 70.2% 24.6% 29.0% 33.3x +8.6% EBS VS ABBV <GO>
UNH UnitedHealth Group Incorporated $410.91 $368.83B 88.6% 4.8% 11.5% 16.4x +6.5% EBS VS UNH <GO>
MRK Merck & Company Inc. $146.33 $361.02B 74.8% 34.3% 20.7% 15.3x +1.3% EBS VS MRK <GO>